Business Description
ISIN : US74276L1052
Total Employee Number:
888Financial Strength
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 2.94 | |||||
Equity-to-Asset | 0.71 | |||||
Debt-to-Equity | 0.23 | |||||
Debt-to-EBITDA | -0.76 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | 4.44 | |||||
Beneish M-Score | -2.47 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 48.6 | |||||
3-Year EBITDA Growth Rate | 4.8 | |||||
3-Year EPS without NRI Growth Rate | 2.9 | |||||
3-Year FCF Growth Rate | 17.5 | |||||
3-Year Book Growth Rate | 13.9 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 24.14 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 22.04 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 47.5 | |||||
9-Day RSI | 50.58 | |||||
14-Day RSI | 51.41 | |||||
3-1 Month Momentum % | -28.01 | |||||
6-1 Month Momentum % | -15.73 | |||||
12-1 Month Momentum % | -47.56 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 6.55 | |||||
Quick Ratio | 5.35 | |||||
Cash Ratio | 3.55 | |||||
Days Inventory | 217.16 | |||||
Days Sales Outstanding | 98 | |||||
Days Payable | 44.82 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -7.9 | |||||
Shareholder Yield % | 0.18 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 64.22 | |||||
Operating Margin % | -33.86 | |||||
Net Margin % | -32.54 | |||||
EBITDA Margin % | -30.45 | |||||
FCF Margin % | -25.17 | |||||
OCF Margin % | -22.04 | |||||
ROE % | -30.16 | |||||
ROA % | -21.96 | |||||
ROIC % | -53.62 | |||||
3-Year ROIIC % | -18.23 | |||||
ROC (Joel Greenblatt) % | -65.56 | |||||
ROCE % | -24.08 | |||||
Moat Score | 5 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 3.55 | |||||
PB Ratio | 3.59 | |||||
Price-to-Tangible-Book | 3.6 | |||||
EV-to-EBIT | -10.11 | |||||
EV-to-EBITDA | -10.44 | |||||
EV-to-Revenue | 3.18 | |||||
EV-to-Forward-Revenue | 2.37 | |||||
EV-to-FCF | -12.63 | |||||
Price-to-GF-Value | 0.25 | |||||
| Price-to-Net-Current-Asset-Value | 4.35 | |||||
| Price-to-Net-Cash | 13.77 | |||||
Earnings Yield (Greenblatt) % | -9.89 | |||||
FCF Yield % | -6.95 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:PRCT
Peter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
PROCEPT BioRobotics Corp Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 337.34 | ||
| EPS (TTM) ($) | -1.94 | ||
| Beta | 1.6047 | ||
| 3-Year Sharpe Ratio | -0.2 | ||
| 3-Year Sortino Ratio | -0.3 | ||
| Volatility % | 38.89 | ||
| 14-Day RSI | 51.41 | ||
| 14-Day ATR ($) | 1.241124 | ||
| 20-Day SMA ($) | 21.4705 | ||
| 12-1 Month Momentum % | -47.56 | ||
| 52-Week Range ($) | 16.665 - 40.1 | ||
| Shares Outstanding (Mil) | 57.27 |
Piotroski F-Score Details
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
PROCEPT BioRobotics Corp Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
PROCEPT BioRobotics Corp Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Annual report for 2026 | 2027-02-26 | In 170 days | ||
| Fourth quarter earnings conference call for 2026 | 2027-02-25 16:30 | In 170 days | ||
| Fourth quarter earnings results for 2026 | 2027-02-25 | In 169 days | ||
| Third quarter earnings conference call for 2026 | 2026-11-04 16:30 | In 57 days | ||
| Third quarter earnings results for 2026 | 2026-11-04 | In 56 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-04 16:30 | 18.38 (-2.60%) | ||
| Second quarter earnings results for 2026 | 2026-08-04 | 18.38 (-2.60%) | ||
| Guidance call for 2026 | 2026-06-16 13:40 | 23.22 (-8.15%) | ||
| General meeting for 2026 | 2026-06-09 13:00 | 28.35 (+2.24%) | ||
| 46th Annual William Blair Growth Stock Conference | 2026-06-02 13:00 | 27.86 (+6.09%) |
PROCEPT BioRobotics Corp Frequently Asked Questions
Guru Commentaries on NAS:PRCT
Procept Biorobotics, the US listed surgical robotics group, has continued to drift through much of the year on very limited negative newsflow, reflecting the general focus away from the sector overall. While Procept did suffer from a temporary industry-wide shortage of saline solution earlier in the year, this proved to be a blip and cannot explain the continued gentle decline for the share price. Our 3-5 year investment horizon is designed to look through these events and we have continued to add to the holding on weakness, backed by solid progress in sales and profits.
PROCEPT BioRobotics was mentioned as one of the smaller market cap and higher multiple positions that faced pressure during the quarter. The letter notes that while they had encouraging operating results, they were offset by broader market conditions affecting life sciences positions. The manager highlights that the healthcare sector is experiencing volatility due to uncertainties introduced by the new administration and personnel turnover at the FDA, which raises questions about drug development and approvals.
Press Release
Articles on PROCEPT BioRobotics Corp
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
